Abstract
Pioglitazone, a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist, is used in the treatment of type 2 diabetes mellitus by reducing insulin resistance. While peripheral edema and fluid retention are well-documented adverse effects, isolated pleural effusion in the absence of heart failure is rare. We present the fourth reported case of a woman in her 60s with type 2 diabetes who developed recurrent left-sided pleural effusion after the initiation and dose escalation of pioglitazone. The effusion resolved completely following discontinuation of the drug. This case underscores the importance of early recognition of drug-induced pleural effusion and timely cessation of the offending agent to prevent morbidity.
Recommended Citation
Chimauriya, Ranjana; Chittal, Abhinandan; Malik, Khalid; DuMont, Tiffany; and Haas, Christopher James
(2025)
"UNVEILING AN UNCOMMON COMPLICATION: PLEURAL EFFUSION SECONDARY TO PIOGLITAZONE USE,"
Journal of Community Hospital Internal Medicine Perspectives: Vol. 15:
Iss.
5, Article 20.
DOI: 10.55729/2000-9666.1541
Available at:
https://scholarlycommons.gbmc.org/jchimp/vol15/iss5/20
DOI
10.55729/2000-9666.1541
